Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity-Reference-Cited by-同舟云学术

Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity

Published:2013-09-04 Issue:4 Volume:134 Page:873-884
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Verschuere Tina¹,Toelen Jaan²,Maes Wim³⁴,Poirier Françoise⁵,Boon Louis⁶,Tousseyn Thomas⁷,Mathivet Thomas⁸,Gerhardt Holger⁸⁹,Mathieu Veronique¹⁰,Kiss Robert¹⁰,Lefranc Florence¹¹,Van Gool Stefaan W.¹²,Vleeschouwer Steven De¹¹³

Affiliation:

1. Department of Neurosciences; Laboratory of Experimental Neurosurgery and Neuroanatomy; KU Leuven; Leuven Belgium

2. Department of Development and Regeneration; KU Leuven; Leuven Belgium

3. Laboratory for Thrombosis Research; IRF Life Sciences (KULAK); Kortrijk Belgium

4. PharmAbs, The KU Leuven Antibody Center; Leuven Belgium

5. Institut Jacques Monod, CNRS, UMR 7592, University Paris Diderot, Sorbonne Paris Cité; Paris France

6. Bioceros BV; Utrecht The Netherlands

7. Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven; Leuven Belgium

8. Department of Oncology, Vascular Patterning Laboratory, Vesalius Research Center, VIB; KU Leuven Belgium

9. Vascular Biology Laboratory; London Research Institute - Cancer Research UK, Lincoln's Inn Fields Laboratories; London United Kingdom

10. Laboratory of Toxicology; Faculty of Pharmacy, Free University of Brussels; Brussels Belgium

11. Department of Neurosurgery; Erasmus University Hospital; Brussels Belgium

12. Department of Microbiology and Immunology; Laboratory of Pediatric Immunology; KU Leuven; Leuven Belgium

13. Department of Neurosciences; KU Leuven; Leuven Belgium

Funder

Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT Vlaanderen)

Klinisch Onderzoeksfonds UZ Leuven

Fund for Scientific Research, Flanders (FWO-V)

Fonds National de la Recherche Scientifique (FRS-FNRS Belgium)

Herman Memorial Research Fund

Olivia Hendrickx Research fund

James E. Kearney Foundation

Belgian Brain Tumor Support (BBTS)

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.28426/fullpdf

Reference42 articles.

1. The 2007 WHO classification of tumours of the central nervous system;Louis;Acta Neuropathol,2007

2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol,2009

3. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial;Ardon;Cancer Immunol Immunother,2012

4. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme;De Vleeschouwer;Clin Cancer Res,2008

5. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials;Ehtesham;Cancer Control,2004

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma;EMBO Molecular Medicine;2023-10-04

2. Single-cell profiling and zebrafish avatars revealLGALS1as immunomodulating target in glioblastoma;2023-05-01

3. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma;Cell Communication and Signaling;2023-04-12

4. Galectin-1: A Traditionally Immunosuppressive Protein Displays Context-Dependent Capacities;International Journal of Molecular Sciences;2023-03-30

5. Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy;International Journal of Molecular Sciences;2022-12-08